EGFR/AURKB-IN-1

• UNSPSC Description:

  EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 occupies the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB, inhibiting the growth, division and metastasis of tumor cells, thus can be used for cancer research[1].

• Target Antigen:

  Aurora Kinase; EGFR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/egfr-aurkb-in-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CN1N=CC=C1C2=CC3=C(N=CN=C3N2)NC4=CC=C(C=C4)OCC5=CC=CC=C5

• Molecular Weight:

  396.44

• References & Citations:

  [1]Kurup S, et al. Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer. Bioorg Med Chem Lett. 2024 Jan 8:129612.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3008543-34-5